Page 28 - Delaware Medical Journal - November/December 2019
P. 28
Collaboration Is Key: Exploring the Delaware Cancer Registry’s Strategic Partnerships to Advance Cancer Surveillance and Control in Delaware
Wilhelmina Ross, PA MPH, CTR; Heather Brown; Anna Stanley-Lee
BACKGROUND
Cancer registry data are integral for assessing cancer burden, planning interventions, directing resources, and evaluating the impact and effectiveness of outreach. This makes registries a keystone partner in cancer surveillance and state initiatives against cancer. Cancer surveillance and control is a multifaceted effort bringing together stakeholders to collect complete, high- quality, and timely data that is used to reduce cancer incidence and improve cancer outcomes. Delaware’s cancer surveillance and control infrastructure
is based upon strong partnerships with multiple agencies, committees, facilities, programs, and their engagement with the general public.
PURPOSE
This study explored the extent of the Delaware Cancer Registry’s (DCR)
of data that increases data quality, timeliness, and completeness and the evidence-based decision making
and outreach in the state. Key DCR
registry data was revealed, as well as the impact it has on creating and evaluating initiatives to combat cancer.
Figure 1
The Inward and Outward Flow of Cancer Data for the DCR 1,2
METHODS
The architecture of Delaware’s cancer surveillance system and control initiatives were analyzed to identify DCR strategic partnerships within the state. The nature
of these partnerships was described qualitatively and quantitatively through the participation, data dissemination, and key outreach programs. Figure 1 illustrates the
the DCR. It depicts entities that report data to the registry and how the registry releases data through linkages and various outreach programs. Many researchers, government agencies, and committees use data collected by the DCR to assess and advance cancer prevention initiatives. Frequencies and
rates were calculated to display the impact registry data has on cancer burden and other evaluation metrics.
268
Del Med J | November/December 2019 | Vol. 91 | No. 6
